[go: up one dir, main page]

CA2858126C - Synthesis of calebin-a and its biologically active analogs - Google Patents

Synthesis of calebin-a and its biologically active analogs Download PDF

Info

Publication number
CA2858126C
CA2858126C CA2858126A CA2858126A CA2858126C CA 2858126 C CA2858126 C CA 2858126C CA 2858126 A CA2858126 A CA 2858126A CA 2858126 A CA2858126 A CA 2858126A CA 2858126 C CA2858126 C CA 2858126C
Authority
CA
Canada
Prior art keywords
sodium
calebin
group
potassium salt
para
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2858126A
Other languages
French (fr)
Other versions
CA2858126A1 (en
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Anju Majeed
Samuel Manoharan Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2858126A1 publication Critical patent/CA2858126A1/en
Application granted granted Critical
Publication of CA2858126C publication Critical patent/CA2858126C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/10—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/10—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C07C67/11—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/62—Use of additives, e.g. for stabilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Disclosed is a simple, economical, industrially scalable green synthetic process for Calebin-A and its biologically active analogs.

Description

SYNTHESIS OF CALEBIN-A AND ITS BIOLOGICALLY ACTIVE ANALOGS
Background of the invention [Para 001] Field of the invention [Para 002] The present invention in general relates to calebinoids. More specifically, the present invention relates to a simple, economical and scalable green process for the synthesis of Calebin A and its biologically active analogs.
[Para 003] Description of prior art [Para 004] Darrick S.H.L. Kim and So-Young Park isolated and identified Calebin-A from Curcuma longa in 2001 (Park S.Y. &
Kim, D.S.H.L., J. Nat. Prod., 2002, 65, 1227 - 1231).
Demethoxycalebin-Al and demethoxycalebin-A2 have been isolated as a pair from Curcuma longa by Feng Qiu et al. in 2007(Zeng, Y.C., Qiu, F., Takahashi, K., Liang, J.M., Qu, G.X. & Yao, X.S., Chem. Pharm. Bull., 2007, 55, 940 -943).By analogy, bisdemethoxycalebin-A may also be present in Curcuma longa though not reported yet. Darrick S.H.L. Kim and Jin Y. Kim synthesized Calebin-A and some of its analogs through a circuitous route (five steps) starting from 1-hydroxyacetone (1) (Kim, D.S.H.L. & Kim, J.Y., Bioorg. Med.
Chem. Lett.,. 2001, 11, 2541 - 2543). The calebinoids having free p-hydroxy group are biologically active. Subsequently D.H.S.L. Kim has patented the pharmaceutical compositions of Calebin-A and its analogs as useful for prevention and treatment of p-amyloid peptide-induced disease [US 7,572,829 B2 (2009). This synthesis has been represented as Scheme 1 (FIG-Prior Art). In short, this prior art synthetic scheme involves protection of 1-hydroxyacetone (1) and vanillin (4) as their tetrahydropyranyl (THP) ethers (2 & 5) using dihydropyran. THP ether of 1-hydroxyacetone (2) is treated with Lithium diisopropylamide (LDA) at low temperature (-78 C) to generate the lithio anion at the a-methyl of the keto group. This lithio anion adds to the aldehyde group of the THP ether of vanillin (5) to give the P-hydroxy-ketone (3). This is dehydrated and deprotected to Feruloylmethanol (6) which is coupled to ferulic acid (7) in the presence of 4-dimethylaminopyridine (DMAP), DMAP-HC1 and N,N-Dicyclohexylcarbodiimide (DCC) to get Calebin-A (10a). The synthetic scheme for Calebin-A discussed herein above is the only known for Calebin-A and its analogs. However, it suffers from the following technical disadvantages.
1. The starting material 1-hydroxyacetone is expensive.
2. The condensation of vanillin with 1-hydroxyacetone involves protection of the hydroxyls as their THP
ethers to avoid Lithium diisopropylamide reacting with hydroxyls.
3. 4-dimethylaminopyridine and N, N-Dicyclohexyl carbodiimide are also expensive.
4. The synthesis involves a minimum of five steps, very low temperature (-78 C), pyrophoric and moisture sensitive reagents.
[Para 005] All aforesaid factors make this process industrially non-feasible for scale up.
[Para 006] It is therefore the principle objective of the present invention to describe a simple, economical, scalable green process for the synthesis of Calebin-A and its analogs.
[Para 007] The present invention fulfills the principle objective and provides further related advantages.
SUMMARY OF THE INVENTION
[Para 008] The present invention discloses a simple, economical, green and industrially scalable synthetic process for Calebin-A and its biologically active analogs.
The disclosed invention has the following advantages. They are, 1. It is a single step synthetic scheme;
2. Economic viability is achieved in terms of low costs of the synthetic process;
3. It is an example of green process that is environmental friendly; and 4. The synthetic scheme assures industrial scalability.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 represents the synthesis of Calebin-A as presented in the prior art.
DESCRIPTION OF THE MOST PREFERRED EMBODIMENT

[Para 009] In the most preferred embodiment, the present invention relates to a general synthetic process for the compound represented by general STR#3 wherein the dotted configuration.... is optionally single bond or double bond;
R1 is selected from the group consisting of OH, OMe, OR, and X wherein R, is alkyl, alkenyl, or alkynyl and X is F, Cl, Br, or I; R2 is selected from group consisting of H, OMe, and OR, wherein R, is alkyl, alkenyl, or alkynyl; R3 is selected from the group consisting of OH, OMe, OR, and X
where Rõ is alkyl, alkenyl, or alkynyl and X is F, Cl, Br, or I;R4 is selected from group consisting of H, OMe, and OR, where R, is alkyl, alkenyl, or alkynyl; and wherein both dotted lines are double bonds and R1 is OH, R2 is OMe, R3 is OH and R4 is H, said synthetic process comprising the steps of A. Mixing the iodomethyl ketone of general structure STR#1 having substituents R1 and R2 as defined vide supra, as dissolved in a solvent with the aqueous solution of the sodium or potassium salt of the acid of general structure (STR#2) [1.0-4.0] mole equivalent, where M-Na or IC+ and R3 and R4 as defined vide supra;

(STR#1) (STR#2) B. Stirring the mixture of Step A at ambient temperature (5 C-30 C) in the presence of a phase transfer catalyst (5 - 10 mole percent with respect to the iodide) and stirring the mixture for 24-72 hours;

C. Separating the organic layer from the product of Step B, washing with aqueous sodium hydrogen carbonate solution followed by drying over anhydrous sodium sulfate, filtering and stripping off the solvent under vacuum followed by crystallization of the crude from ethyl acetate or ethanol to get compound represented by general structure STR#3.

(STR#3) [Para 0010] In another most preferred embodiment, the present invention relates to a simple, economical, industrially scalable green synthetic scheme for Calebin-A
and its demethoxy analogs as represented below.
o O Phase transfer 116 I R' 49 ` Om catalyst/solvent/water 114 HO 41" (8) HO (8) 0 OH
o M-Na* (or) K.
(8a) where R=OCM30 HO 4111"
(8b) where R=R (9a) where R'-0C143 Calebin A and its analogs (9b) where R.1-11 (10a): FtDC113;R.-OCH3 (10b): R=OCM3;R'-11 (10C): R=Ei ;R'=0C143 (10d): R.-11 ;R'=1-1 [Para 0011] Specifically, the present invention relates to a general synthetic process for Calebin-A (Feruloylmethyl ferulate-10a) and its demethoxy analogs (Feruloylmethyl 4-hydroxycinnamate-10b, 4-Hydroxycinnamoylmethyl ferulate-10c and 4-Hydroxycinnamoylmethyl 4-hydroxycinnamate-10d), said process comprising the steps of:
A. Mixing feruloyl or 4-hydroxycinnamoyliodomethane (8a or 8b, 0.015 mol) dissolved in a solvent with the aqueous solution of sodium or potassium salt of ferulic acid or 4-hydroxycinnamic acid ((9a or 9b), 1.0 - 4.0 mole equivalent);

B. Stirring the mixture of Step A at ambient temperature (50C-300C) in the presence of a phase transfer catalyst (5 - 10 mole percent with respect to the iodide) and stirring the mixture for 24-72 hours;
C. Separating the organic layer from the product of Step B, washing with aqueous sodium hydrogen carbonate solution followed by drying over anhydrous sodium sulfate, filtering and stripping off the solvent under vacuum followed by crystallization of the crude from ethyl acetate Or ethanol to get Calebin-A
(Feruloylmethyl ferulate-10a) or its demethoxy analogs (Feruloylmethyl 4-hydroxycinnamate-10b, 4-Hydroxycinnamoylmethyl ferulate-10c and 4-Hydroxycinnamoylmethyl 4-hydroxycinnamate-10d)as pale yellow crystalline solids in 50 7 60 96 yield.
[Para 0012] In specific embodiments, the ideal solvent for dissolving Feruloyl or 4-hydroxycinnamoyliodomethane as mentioned herein above is one selected from group comprising dichloromethane, chloroform, ethyl acetate and tetrahydrofuran among others.
[Para 0013] In further specific embodiments, ideal phase transfer catalysts used in aforementioned synthetic scheme is one selected from group comprising tetrabutylammonium bromide, tetrabutylammonium hydrogensulfate, benzyltributyl ammonium chloride, benzyltriethylammonium chloride and benzyltrimethyl ammonium chloride among others.
[Para 00141 Specific examples of the general synthetic scheme for Calebin A and its demethoxy analogs discussed herein above are provided in the following paragraphs.
Feruloyliodomethane and 4-Hydroxycinnamoyliodomethane used in examples included herein below were prepared according to a reported method (Wang, Z., Yin, G., Qin, J., Gao, M., Cao, L & Wu, A., Synthesis, 2008, 22, 3675 - 3681).
[Para 0015] EXAMPLE 1 [Para 0016] Calebin-A (Feruloylmethyl ferulate, 10a) [Para 0017] Calebin-A (10a) was prepared by reacting feruloyliodomethane with sodium or potassium salt of ferulic acid with reaction steps and conditions maintained as mentioned in the general synthetic scheme discussed herein above in Para 0010. The yield of the product was 60 96.

[Para 0018] Calebin-A (Feruloylmethyl ferulate, 10a): Pale yellow solid; m.p. 138 - 140 C;
1H NMR (Acetone-d6, 300 MHz): 6 3.902 (s, 3H), 3.929 (s, 3H), 5.106 (s, 2H), 6.518 (d, J = 15.9 Hz, 1H), 6.856 (d, J
= 16.2 Hz, 1H), 6.886 (d, J = 8.4 Hz, 1H), 6.892 (d, J = 8.4 Hz, 1H), 7.180 (dd, J = 8.4 Hz, 1.8 Hz, 1H), 7.214 (dd, J =
8.4 Hz, 1,8 Hz, 1H), 7.375 (d, J = 1.8 Hz, 1H), 7.386 (d, J
= 1.8 Hz, 1H), 7.666 (d, J = 16.2 Hz, 1H), 7.671 (d, J =
15.9 Hz, 1H), 8.246 (s, 1H), 8.309 (s, 1H).
[Para 0019] "C NMR (Acetone-d6, 75 MHz): 5 56.267, 56.296, 67.927, 111.290. 111.524, 116.077, 116.201, 120.322, 124.165, 124.494, 127.349, 127.408, 144.389, 146.505, 148.752, 150.209, 150.501, 166.898, 192.963.
[Para 0020] LC-MS (+APCI): m/z 385 (M++1); LC-MS (-APCI):
m/z 383 (le-1).
Me0 OH

0 '. 0 HO
OMe (10a) [Para 0021] EXAMPLE 2 [Para 0022] Demethoxycalebin-Al (Feruloylmethyl 4-hydroxycinnamate 10b) [Para 0023] Demethoxycalebin-Al (Feruloylmethyl 4-hydroxycinnamate 10b) was prepared by reacting feruloyliodomethane with sodium or potassium salt of 4-hydroxycinnamic acid with reaction steps and conditions maintained as mentioned in the general synthetic scheme discussed herein above in Para 0010. The yield of the product was 50 -lc.

OH

HO
OMe (10b) [Para 0024] Demethoxycalebin-Al (Feruloylmethyl 4-hydroxycinnamate, 10b): Pale yellow solid; m.p. 181.4 -183.4 C;
11-1 NMR (DMSO-d6, 300 MHz): 5 3.815 (s, 3H), 5.132 (s, 2H), 6.508 (d, J = 16.2 Hz, 1H), 6.813 (d, J
= 8.4 Hz, 2H), 6.825 (d, J = 8.4 Hz, 1H), 6.842 (d, J = 16.8 Hz, 1H), 7.173 (dd, J = 8.4 Hz, 1.5 Hz, 1H), 7.336 (d, J = 1.5 Hz, 1H), 7.592 (d, J = 8.4 Hz, 2H), 7.623 (d, J = 16.8 Hz, 1H), 7.626 (d, J = 16.2 Hz, 1H), 9.814 (s, 1H), 10.135 (s, 1H).
[Para 0025] 13C NMR (DMSO-d6, 75 MHz): 6 55.764, 55.793, 67.263, 111.431, 113.656, 115.778, 115.961, 119.541, 123.837, 125.162, 125.763, 130.637, 143.959, 145.643, 148.110, 149.925, 160.121, 166.189, 192.753.
[Para 0026] LC-MS (+APCI): m/z 355 (le+1); LC-MS (-APCI):
m/z 353 (M+-1).
[Para 0027] EXAMPLE 3 [Para 0028] Demethoxycalebin-A2 (4-Hydroxycinnamoylmethyl ferulate 10c) [Para 0029] Demethoxycalebin-A2 (4-Hydroxycinnamoylmethyl ferulate 10c) was prepared by reacting 4-hydroxycinnamoyliodomethane with sodium or potassium salt of ferulic acid with reaction steps and conditions maintained as mentioned in the general synthetic scheme discussed herein above in Para 0010. The yield of the product was 50.

Me0 OH

'\. illii HO
(10c) [Para 0030] Demethoxycalebin-A2 (4-Hydroxycinnamoylmethyl ferulate, 10c): Cremish solid, m.p. 175.7 - 177.7 C.
[Para 0031] IH NMR (DMSO-d6, 300 MHz): 5 3.819 (s, 3H), 5.127 (s, 2H), 6.591 (d, J = 16.2 Hz, 1H), 6.773 (d, J = 16.2 Hz, 1H), 6.807 (d, J = 8.4 Hz, 1H), 6.825 (d, J = 8.4 Hz, 2H), 7.157 (dd, J . 8.4 Hz, 1.8 Hz, 1H), 7.357 (d, J = 1.8 Hz, 1H), 7.589 (d, J . 8.4 Hz, 2H), 7.614 (d, J . 16.2 Hz, 1H), 7.631 (d, J = 16.2 Hz, 1H), 9.731 (s, 1H), 10.207 (s, 1H).
[Para 0032] IIC NMR (DMSO-d6, 75 MHz): 5 55.786, 55.815, 67.249, 111.372, 113.934, 115.632, 116.042, 119.211, 123.450, 125.236, 125.631, 130.835, 143.601, 145.936, 148.058, 149.596, 160.370, 166.197, 192.775.
[Para 00331 LC-MS (+APCI): m/z 355 (M++1); LC-MS (-APCI):
m/z 353 (M+-1).
[Para 0034] EXAMPLE 4 [Para 0035] Bisdemethoxycalebin-A (4-Hydroxycinnamoylmethyl 4-hydroxycinnamate, 10d) [Para 0036] Bis-demethoxycalebin-A (4-Hydroxycinnamoylmethyl 4-hydroxycinnamate, 10d) was prepared by reacting 4-hydroxycinnamoyliodomethane with sodium or potassium salt of 4-hydroxycinnamic acid with reaction steps and conditions maintained as mentioned in the general synthetic scheme discussed herein above in Para 0010. The yield of the product was 55%.
OH

.\. el HO

(10d) [Para 0037] Bisdemethoxycalebin-A (4-Hydroxycinnamoylmethyl 4-hydroxycinnamate, 10d): Pale yellow solid: m.p. 289 -291 C;
[Para 0038] IH NMR (DMSO-d6, 300 MHz): 6 5.120 (s, 2H), 6.507 (d, J = 15.9 Hz, 1H), 6.771 (d, J = 15.9 Hz, 1H), 6.813 (d, J = 8.4 Hz, 2H), 6.825 (d, J = 8.4 Hz, 2H), 7.587 (d, J =
8.4 Hz, 4H), 7.626 (d, J = 15.9 Hz, 2H), 10.140 (s, 1H), 10.201 (s, 1H).
[Para 0039] I3C NMR (DMSO-d6, 75 MHz): 6 67.293, 113.648, 115.976, 116.086, 119.219, 125.177, 125.265, 130.645, 130.879, 143.645, 145.658, 160.136, 160.407, 166.204, 192.819.
[Para 0040] LC-MS (+APCI): m/z 325 (M++1); LC-MS (-APCI):
m/z 323 (M+-1).
[Para 0041] The examples included herein substantiate the most preferred embodiment of the invention. These examples should not be construed to limit the scope of variations possible in the practice of the instant invention. The examples are thus illustrative and not exhaustive.

Claims (8)

We Claim,
1. A general synthetic process for the compound represented by general STR#3 wherein the dotted configuration.... is optionally single bond or double bond; R1 is selected from the group consisting of OH, OMe, OR a and X wherein R a is C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl and X is F, Cl, Br, or I; R2 is selected from group consisting of H, OMe, and OR a wherein R a is C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl; R3 is selected from the group consisting of OH, OMe, OR a and X where R a is 1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl and X is F, Cl, Br, or I; R4 is selected from group consisting of H, OMe, and OR, where R a is C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl; and wherein both dotted lines are double bonds and R1 is OH, R2 is OMe, R3 is OH and R4 is H, said synthetic process comprising the steps of A. Mixing the iodomethyl ketone of general structure STR#1 having substituents R1 and R2 as defined vide supra, as dissolved in a solvent with the aqueous solution of 1.0 -4.0 mole equivalent of the sodium or potassium salt of the acid of general structure (STR#2), where M=Na+ or K+ and R3 and R4 as defined vide supra;
B. Stirring the mixture of Step A at a temperature of 5°C-30°C in the presence of 5 - 10 mole percent with respect to the iodide of a phase transfer catalyst and stirring the mixture for 24-72 hours;
C. Separating the organic layer from the product of Step B, washing with aqueous sodium hydrogen carbonate solution followed by drying over anhydrous sodium sulfate, filtering and stripping off the solvent under vacuum followed by crystallization of the crude from ethyl acetate or ethanol to get compound represented by general structure STR#3
2.A general synthetic process for Calebin-A or its demethoxy analogs selected from Feruloylmethyl 4-hydroxycinnamate, 4-Hydroxycinnamoylmethyl ferulate and 4-Hydroxycinnamoylmethyl 4-hydroxycinnamate, said process comprising the steps of:
A. Mixing 0.015 mol of feruloyl or 4-hydroxycinnamoyliodomethane dissolved in a solvent with the aqueous solution of 1.0 - 4.0 mole equivalent of sodium or potassium salt of ferulic acid or 4-hydroxycinnamic acid ;
B. Stirring the mixture of Step A at a temperature of 5°C-30°C in the presence of 5 - 10 mole percent with respect to the iodide of a phase transfer catalyst and stirring the mixture for 24-72 hours;
C. Separating the organic layer from the product of Step B, washing with aqueous sodium hydrogen carbonate solution followed by drying over anhydrous sodium sulfate, filtering and stripping off the solvent under vacuum followed by crystallization of the crude from ethyl acetate or ethanol to get Calebin-A or its demethoxy analogs as defined above as pale yellow crystalline solids in 50 - 60 % yield.
3.The process according to claim 2 wherein synthesis of Calebin-A involves reacting feruloyliodomethane with sodium or potassium salt of ferulic acid in step A.
4. The process according to claim 2 wherein synthesis of Feruloylmethyl 4-hydroxycinnamate involves reacting feruloyliodomethane with sodium or potassium salt of 4-hydroxycinnamic acid in step A.
5.The process according to claim 2 wherein synthesis of 4-Hydroxycinnamoylmethyl ferulate involves reacting 4-hydroxycinnamoyliodomethane with sodium or potassium salt of ferulic acid in step A.
6.The process according to claim 2 wherein synthesis of 4-Hydroxycinnamoylmethyl 4-hydroxycinnamate involves reacting 4-hydroxycinnamoyliodomethane with sodium or potassium salt of 4-hydroxycinnamic acid in step A.
7. The process according to any one of claims 1 and 2 wherein the solvent used in step A is one selected from the group comprising dichloromethane, chloroform, ethyl acetate and tetrahydrofuran.
8. The process according to any one of claims 1 and 2 wherein the phase transfer catalyst used in step B is one selected from the group comprising tetrabutylammonium bromide, tetrabutylammonium hydrogensulfate, benzyltributyl ammonium chloride, benzyltriethylammonium chloride and benzyltrimethyl ammonium chloride.
CA2858126A 2014-07-01 2014-07-30 Synthesis of calebin-a and its biologically active analogs Expired - Fee Related CA2858126C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/320,649 2014-07-01
US14/320,649 US9365486B2 (en) 2014-07-01 2014-07-01 Synthesis of calebin-A and its biologically active analogs

Publications (2)

Publication Number Publication Date
CA2858126A1 CA2858126A1 (en) 2016-01-01
CA2858126C true CA2858126C (en) 2018-06-19

Family

ID=51352423

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858126A Expired - Fee Related CA2858126C (en) 2014-07-01 2014-07-30 Synthesis of calebin-a and its biologically active analogs

Country Status (7)

Country Link
US (1) US9365486B2 (en)
EP (1) EP2963007B1 (en)
JP (1) JP6490927B2 (en)
KR (1) KR101629561B1 (en)
AU (1) AU2014203764B2 (en)
CA (1) CA2858126C (en)
EA (1) EA027726B1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299706B2 (en) * 2018-02-23 2022-04-12 Sami-Sabinsa Group Limited Microbial bioconversion of curcuminoids to calebin-A
JP7360856B2 (en) * 2019-09-05 2023-10-13 東ソー・ファインケム株式会社 Method for producing fluorine-containing (meth)acrylic esters
EP4377291A4 (en) * 2021-05-28 2025-08-27 Muhammed Majeed PROCESS FOR THE SYNTHESIS OF CALEBIN-A AND ITS INTERMEDIATES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4830611B1 (en) * 1969-11-27 1973-09-21
US4334079A (en) * 1980-11-03 1982-06-08 Eli Lilly And Company Synthesis of substituted benzyl esters
JPS57197258A (en) * 1981-05-29 1982-12-03 Taiho Yakuhin Kogyo Kk Sulfonic ester derivative and its preparation
JP2600327B2 (en) * 1988-09-07 1997-04-16 住友化学工業株式会社 Optically active carboxylic acid esters and method for producing the same
JPH03188044A (en) * 1989-12-18 1991-08-16 Tousoo Yuki Kagaku Kk Production of acyloxyaliphatic hydrocarbon
US6887898B1 (en) 1999-10-22 2005-05-03 Darrick S. H. L. Kim Pharmaceutical compositions useful in prevention and treatment of beta-Amyloid protein-induced disease
EP1895849A4 (en) * 2005-06-15 2009-11-11 Darrick S H L Kim Methods for treatment of beta-amyloid protein-induced ocular disease
JP5158324B2 (en) * 2007-06-29 2013-03-06 東ソー株式会社 Process for producing chain aliphatic diol
CN102766048A (en) * 2012-07-20 2012-11-07 广州市博兴化工科技有限公司 (Methyl) acrylate compound containing ketone carbonyl group as well as preparation method and application thereof

Also Published As

Publication number Publication date
AU2014203764A1 (en) 2016-01-21
NZ627247A (en) 2016-01-29
US9365486B2 (en) 2016-06-14
US20160002141A1 (en) 2016-01-07
HK1217689A1 (en) 2017-01-20
EP2963007B1 (en) 2019-10-09
KR20160003536A (en) 2016-01-11
EA201491913A1 (en) 2016-01-29
AU2014203764B2 (en) 2018-10-18
KR101629561B1 (en) 2016-06-10
EA027726B1 (en) 2017-08-31
JP6490927B2 (en) 2019-03-27
EP2963007A1 (en) 2016-01-06
JP2016014003A (en) 2016-01-28
CA2858126A1 (en) 2016-01-01

Similar Documents

Publication Publication Date Title
WO2013091282A1 (en) Cajanine structure analogous compound, preparation method and use
CN105273025B (en) A kind of intermediate and its preparation method and application preparing cangrelor
CA2858126C (en) Synthesis of calebin-a and its biologically active analogs
JP2017513863A (en) Polymorphic forms of 4,5-dihydro-1H-pyrrolo [2,3-F] quinoline-2,7,9-tricarboxylic acid and its disodium salt, methods for their preparation and their use
CN107778279B (en) Preparation method of atorvastatin calcium intermediate
PL236839B1 (en) 7-pentoxy-naringenin and 7,4'-dipentoxy-naringenin and method for simultaneously obtaining 7-pentoxy-naringenin and 7,4'-dipentoxy-naringenin
PL236846B1 (en) 7-dodecanoxy-naringenin and 7,4'-didodecanoxy-naringenin and method for simultaneously obtaining 7-dodecanoxy-naringenin and 7,4'-didodecanoxy-naringenin
KR101728443B1 (en) Method for Producing Benzyl Ester 2-aminonicotinicotinate Derivative
JP6212429B2 (en) Process for producing 1,3,4,5-tetracaffeoylquinic acid and intermediate compounds
HK1217689B (en) Synthesis of calebin-a and its biologically active analogs
CN102212060A (en) Method for preparing lafutidine by virtue of aminolysis
NZ627247B (en) Synthesis of calebin-a and its biologically active analogs
CN103420871B (en) Method for preparing (5R)-6-cyanogroup-5-hydroxy-3-oxocaproic acid tert-butyl ester
CN100434427C (en) A kind of benzopyran compound and its preparation method
CN101830872A (en) Synthetic method of 3-hydroxyl benzofuran derivatives
US11434217B2 (en) Method for synthesis of lobaric acid and analog thereof
CN105566261A (en) Preparation method of combretastatin furan type analogues
CN102491941B (en) Preparation method of N-methoxy-N-methyl-1-p-toluenesulfonyl piperidine-4-amide
CN101525281B (en) Synthetic method of natural products of AB5046A and AB5046B with herbicidal activity
CN102690252A (en) Preparation method of stiripentol
PL211582B1 (en) Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereof
CN103554036A (en) Preparation method of 2-chloro-4-substituted pyrimidine compound
KR20140112769A (en) Atorvastatin isopropyl amine salt, the preparation method thereof and the preparation method of Atorvastatin hemicalcium salt using the same
CN103922911A (en) (1E,4E)-1,5-di(o-bromo-m-methoxy-phenyl)-1,4-pentadiene ketone compound and synthesis method thereof
PL221297B1 (en) Aromatic 2-hydroxy-5-methyl-9-oxabicyclo[4.3.0]nonan-8-one and method of obtaining aromatic hydroxylactone

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20210730